TRADELABOR has more than 20 years of experience in the control and treatment of air, working with an experienced and qualified technical staff and with the most advanced technology in this area, which together guarantee the quality of the services provided.
In this report, researchers report 5-year outcomes of the Phase III CheckMate 067, which found that nivolumab plus ipilimumab or nivolumab alone resulted in longer progression-free and overall survival than ipilimumab alone for patients with advanced melanoma.
Patients with previously untreated advanced melanoma were randomly assigned to receive a regimen of either nivolumab plus ipilimumab every 3 weeks for four doses, followed by nivolumab; nivolumab plus ipilimumab-matched placebo; or ipilimumab plus nivolumab-matched placebo.
We build Industrial Site for Cannabis Oil Extraction. See more at: PHARMAIUM
The primary endpoints were progression-free survival and overall survival in the nivolumab-plus-ipilimumab group and in the nivolumab group, as compared with the ipilimumab group. At a minimum follow-up of 5 years, the median overall survival was more than 60.0 months (median not reached) in the nivolumab-plus-ipilimumab group and 36.9 months in the nivolumab group, versus 19.9 months in the ipilimumab group.
Overall survival at 5 years was 52% in the nivolumab-plus-ipilimumab group, 44% in the nivolumab group, and 26% in the ipilimumab group. No sustained deterioration of health-related quality of life was observed during or after treatment with nivolumab plus ipilimumab or with nivolumab alone.
The researchers concluded, “Among patients with advanced melanoma, sustained long-term overall survival at 5 years was observed in a greater percentage of patients who received nivolumab plus ipilimumab or nivolumab alone than in those who received ipilimumab alone, with no apparent loss of quality of life in the patients who received regimens containing nivolumab.”New England Journal of Medicine (10/17/19) Vol. 381, No. 16, P. 1535 Larkin, James; Chiarion-Sileni, Vanna; Gonzalez, Rene; et al.https://www.nejm.org/doi/full/10.1056/NEJMoa1910836
Continue at: https://www.pharmacytoday.org/drugs/drugs-2019-10-18-story3
The text above is owned by the site above referred.
Here is only a small part of the article, for more please follow the link